1074 related articles for article (PubMed ID: 32757981)
1.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
2. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
3. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
6. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
7. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
Wang J
J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
[TBL] [Abstract][Full Text] [Related]
8. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
9. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
Hall DC; Ji HF
Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562
[TBL] [Abstract][Full Text] [Related]
10. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
[TBL] [Abstract][Full Text] [Related]
11. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
Hosseini FS; Amanlou M
Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
[TBL] [Abstract][Full Text] [Related]
12. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
[TBL] [Abstract][Full Text] [Related]
13. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
Shah B; Modi P; Sagar SR
Life Sci; 2020 Jul; 252():117652. PubMed ID: 32278693
[TBL] [Abstract][Full Text] [Related]
14. Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19.
Tariq A; Mateen RM; Afzal MS; Saleem M
Int J Infect Dis; 2020 Sep; 98():166-175. PubMed ID: 32579907
[TBL] [Abstract][Full Text] [Related]
15. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
[TBL] [Abstract][Full Text] [Related]
17. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
18. Alkaloids from
Borquaye LS; Gasu EN; Ampomah GB; Kyei LK; Amarh MA; Mensah CN; Nartey D; Commodore M; Adomako AK; Acheampong P; Mensah JO; Mormor DB; Aboagye CI
Biomed Res Int; 2020; 2020():5324560. PubMed ID: 33029513
[TBL] [Abstract][Full Text] [Related]
19. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
20. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
